Through the whole transcriptome analysis of the patients with HRD tumors, we identified that CXCL11 expression could be a reliable prognostic risk gene in the TCGA‐OSC cohort and its efficacy was proved in the GEO‐OSC cohorts. The gene discussed is CXCL11; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.